SCHEMBL3886748

SCHEMBL3886748

COc1ccn2c(C(=O)C(=O)Nc3ccc(C)cc3)c(-c3ccccc3)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 3/20 0.49
THRB P10828 1/20 0.47
MAPT P10636 5/20 0.47
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 4/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
TP53 P04637 2/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
GAA P10253 2/20 0.41
POLB P06746 2/20 0.41
AURKA O14965 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3890527 0.94 THRB (0.49) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645232 0.88 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645639 0.85 SMN1; SMN2 (0.47) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645645 0.85 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645379 0.85 THRB (0.65) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1644769 0.84 THRB (0.61) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1644306 0.81 THRB (0.55) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645256 0.80 LMNA (0.51) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1644516 0.80 ALDH1A1 (0.63) SMN1; SMN2LMNAHTTTHRBMAPT
SCHEMBL1645339 0.80 THRB (0.61) SMN1; SMN2LMNAHTTTHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885LMNA 2694/4885HTT 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.